FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid Leukemia

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 1, 2012, Pages 84-89

  Zhong, Ling ^a   Jia, Yong Qian ^a   Meng, Wen Tong ^a   Ni, Xun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD56 ANTIGEN; CD7 ANTIGEN; FLT3 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CHINA; DNA SEQUENCE; ETHNOLOGY; FEMALE; GENETICS; HUMAN; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; TANDEM REPEAT;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIGENS, CD56; ANTIGENS, CD7; BASE SEQUENCE; CASE-CONTROL STUDIES; CHINA; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; MUTATION; SEQUENCE ANALYSIS, DNA; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84856044267     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0700-OA     Document Type: Article

References (23)

1. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11(10):1605-1609. (Pubitemid 27458595)
2. Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23(26): 6285-6295. (Pubitemid 46218838)
3. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911-1918. (Pubitemid 27019637)
4. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukemia define a high-risk group. Br J Heamatol. 2000;111(1):190-195.
5. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326- 4335. (Pubitemid 34627197)
6. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665. (Pubitemid 37328820)
7. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624-631. (Pubitemid 30102913)
8. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and NRAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074-3080. (Pubitemid 29200800)
9. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752-1759.
10. Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci. 2004; 61(23):2932-2948.
11. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplication in the Flt3 gene. Leukemia. 2000;14(4):675-683. (Pubitemid 30195459)
12. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19(8):1345-1349. (Pubitemid 41136326)
13. Kiyoi H, Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol. 2006;83(4):301-308. (Pubitemid 43807573)
14. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380. (Pubitemid 35434129)
15. Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102(7):2387-2394. (Pubitemid 37193574)
16. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemia. Exp Mol Pathol. 2005; 79(1):39-41. (Pubitemid 40984750)
17. Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemia with FLT3/ITD mutation. Am J Clin Pathol. 2008;129(4):624-629. (Pubitemid 352029282)
18. Sallmyr A, Fan J, Datta K, et al. Internal tandem duplication of FLT3 (FLT3/ ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood. 2008;111(6):3173-3182.
19. Erba HP. Prognostic fators in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program. 2007; 420-428.
20. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66. (Pubitemid 35177429)
21. Meshhinchi S, Stirewalt DL, Alonzo TA, et al. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 2008;111(10):4930-4933.
22. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107(9):3724-3726.
23. Vempati S, Reindl C, Kaza SK, et al. Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood. 2007;110(2):686-694. (Pubitemid 47105408)